• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

Exclusive – EU regulator to decide on Pfizer booster at the start of October – source

September 23, 2021 by David Barret Leave a Comment

September 23, 2021

By Emilio Parodi and Francesco Guarascio

BRUSSELS (Reuters) – The European Medicines Agency (EMA) expects to decide in early October on the possible use of a booster dose of the Pfizer-BioNTech COVID-19 vaccine, a source with direct knowledge of the matter told Reuters.

It will be the EU drugs regulator’s first decision on boosters, the source said, after the U.S. Food and Drug Administration on Wednesday authorized a third dose of Pfizer for those 65 and older, all people at high risk of severe disease, and others who are regularly exposed to the virus.

“EMA’s decision on the third dose of Pfizer is expected for the beginning of October,” the source said, declining to be named because of the sensitivity of the matter.

Pfizer declined to comment, while BioNTech was not immediately available for comment.

The EU regulator said on Sept. 6 it had begun its evaluation of data submitted by Pfizer and BioNTech for a booster dose to be given six months after the second dose in people 16 years of age and older.

Moderna is also expected to submit data to the EMA this month on its booster dose, an EU document said.

In an opinion issued in early September and republished by the EMA, the European Centre for Disease Prevention and Control (ECDC) said there was no urgent need to administer booster doses to fully vaccinated individuals in the general population.

But it also noted that additional doses should already be considered for people with severely weakened immune systems as part of their primary vaccination.

Many EU states have already decided to administer a booster dose despite facing higher legal risks without a formal decision to do so by the EMA.

The EU has signed three deals with Pfizer and BioNTech for a total of 2.4 billion doses.

The latest contract covers the supply of at least 900 million shots, a large part of which is likely to be needed only if boosters are considered necessary, or if new virus variants emerge against which existing vaccination is not effective.

Over 70% of the EU’s adult population has already been fully vaccinated, and the bloc has secured an ample supply of vaccines from several manufacturers.

The ECDC has said crucial data on the need and safety of boosters are still missing, in part because it is not yet fully clear how long vaccines protect against the virus.

(Reporting by Emilio Parodi and Francesco Guarascio @fraguarascio; Additional reporting by Ludwig Burger; Editing by Josephine Mason and Jan Harvey)

Source Link Exclusive – EU regulator to decide on Pfizer booster at the start of October – source

David Barret
David Barret

Related posts:

  1. IFRC urges urgent global humanitarian support for Afghanistan
  2. Global reinsurance rates to keep rising next year – Moody’s
  3. Pro-Putin party heads for Russian election win after Navalny clampdown
  4. Italy reports 26 coronavirus deaths on Sunday, 3,838 new cases

Filed Under: News

Reader Interactions

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Primary Sidebar

  • First-Of-Its-Kind Evidence Shows Bees Can Learn “Morse Code” – Well, Kinda
  • Humans Have A “Seventh Sense” That Lets You Touch Things From A Distance
  • The Longest Place Name Has 111 Letters – And It’s Visited By Millions Of People Each Year
  • We Now Know Why Neanderthal Faces Looked So Different To Our Own
  • Why Does Africa Have So Many Of The World’s Largest Land Animals?
  • This “Ant-Mimicking” Spider Produces Its Own Kind Of Milk And Nurses Its Babies
  • 1972 Was The Longest Year In Modern History – Here’s Why
  • Why Did “Magic Mushrooms” Evolve To Be Hallucinogenic – What’s In It For The Mushrooms?
  • Why Can’t You Domesticate All Wild Animals? The Process Relies On 6 Characteristics Few Mammals Possess
  • Meet Some Of Earth’s Mightiest Predators
  • Canada Officially Loses Its Measles Elimination Status After Nearly 30 Years. The US Is Not Far Behind
  • Two “Anomalies” Detected In Egypt’s Menkaure Pyramid Using Electrical Resistance Tomography
  • Invasive “Tree Of Heaven” Unleashes Hell As “Double Invasion” Sweeps Across Virginia
  • Hamman’s Crunch: A Man Covered His Nose And Mouth Whilst Sneezing And Ended Up In Hospital
  • “One Of The Most Beautiful Experiments In Evolutionary Biology”: What The Peppered Moth Taught Us About Evolution
  • Why Do Microwaved Eggs Explode When You Bite Into Them?
  • First-Ever At-Home LSD Microdosing Trial For Depression Sees 60 Percent Improvement In Symptoms
  • People Are Just Learning What A Baby Turkey Is Called
  • Enceladus’s North Pole Is Leaking Heat, Indicating Its Ocean Is Ancient And Boosting Prospects For Life
  • Speaking Multiple Languages May Be A Secret Weapon Against The Ravages Of Old Age
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version